Follow Coherus Oncology, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
6 Stories in coverage 74 approved Programs 62 recruiting Registered trials 8-K Nov 12 Latest SEC filing Nov 9 Latest story
Timeline 6 Pipeline 7 Trials 6
All6 Regulatory2 Trials and readouts2 Filings and people5
Pipeline by stage
Approved 4 Phase 2 1 Phase 1 1 Other 1
Details
Headquarters Redwood City, CA Incorporated Delaware Industry Biological Products, (No Diagnostic Substances) Formerly Coherus BioSciences, Inc. (to 2025); BioGenerics, Inc. (to 2012) Also known as BioGenerics, Inc., CHRS, Coherus BioSciences, Inc. How the company describes itself Coherus Oncology is a commercial-stage oncology company developing the PD-1 inhibitor toripalimab and a pipeline of antibody immunotherapies targeting liver, head and neck, colorectal, and gastrointestinal cancers. The company has mid-stage candidates including an IL-27 antagonist and an anti-CCR8 antibody. source